GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.
US-based affordable medicine developer EQRx secured $500m yesterday in a series B round featuring healthcare software producer Nextech and GV, a corporate vehicle for internet and technology group Alphabet. The round included all the participants in the $200m series A round EQRx disclosed when it emerged from stealth in January 2020, including Andreessen Horowitz, Section…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.